IceCure Medical Ltd (ICCM) AI Stock Analysis
ICCM AI stock analysis summary
AI ResearchIceCure Medical Ltd (ICCM) is a medical device company developing cryoablation technology for freezing tumors. The business generates $3.9M in trailing twelve months revenue but remains unprofitable, reporting a net loss of -$15.1M in FY2025. It closed the June 30, 2026 quarter with $12.0M in cash and short-term investments against $90,000 in total debt.
- Market cap
- $4.9M
- Revenue (TTM)
- $3.9M
- P/E
- —
- 1Y return
- -95.7% S&P 500 16.8%
- Avg. target
- $22.67 2038.4% vs last close
Bull case
- Quarterly revenue grew 72.8% year-over-year in the period ended June 30, 2026.
- Analysts project next fiscal year revenue to expand by 105.0% to $8.8M.
- The company holds $12.0M in cash and short-term investments against only $90,000 in total debt.
Bear case
- The company generated negative free cash flow of -$14.6M in FY2025.
- IceCure Medical delivered 0 EPS beats across the last 4 reported quarters.
- Gross margin has weakened continuously from 53.0% in FY2021 to 36.3% in FY2025.
What IceCure Medical does
IceCure Medical Ltd, based in Caesarea, Israel, is a medical device company specializing in the research, development, and commercialization of advanced cryoablation technologies that freeze tumors within the human body. Founded in 2006, the company focuses on its proprietary ProSense system, which offers a specialized minimally invasive cryoablation solution tailored for the treatment of breast tumors. IceCure Medical operates globally to provide oncological care solutions that empower healthcare professionals and improve patient outcomes through ongoing clinical research and product development.
Growth and profitability
IceCure Medical's revenue fell at a 5-year CAGR of 2.7% between FY2020 and FY2025. Annual revenue decreased from $4.1M in FY2021 to $3.1M in FY2022, before slightly recovering to $3.2M in FY2023, $3.3M in FY2024, and $3.4M in FY2025. Gross margin contracted from 53.0% in FY2021 to 36.3% in FY2025. Net losses remained substantial, posting -$15.1M in FY2025 with an operating margin of -446.7% and R&D spending of $7.4M. For the latest quarter ended June 30, 2026, quarterly revenue grew 72.8% year-over-year, while trailing twelve months revenue reached $3.9M with an operating margin of -487.8% and diluted EPS of -$6.84.
Balance sheet and cash flow
As of June 30, 2026, IceCure Medical held $12.0M in cash and short-term investments alongside total debt of $90,000, leaving net cash at $11.9M. Total assets stood at $17.7M and shareholders' equity was $11.9M, supporting a current ratio of 2.87 and a debt-to-equity ratio of 0.01. Operating cash flow in FY2025 was -$14.6M, matching free cash flow of -$14.6M after capital expenditures of $36,000. Over the past five years, the company's share count fell 91.4%.
Valuation and performance
IceCure Medical carries a market capitalization of $4.9M and an enterprise value of -$3.5M. The stock trades at a price-to-sales multiple of 1.2x and an EV-to-revenue multiple of 0.6x, compared to a median price-to-sales multiple of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 0.7x. Over the past year, the stock fell 95.7%, while the S&P 500 returned 16.8%. Over a 5-year span, the shares dropped 99.4% versus an 83.0% gain for the benchmark index.
What analysts expect
Wall Street coverage includes 2 Strong Buy ratings, 1 Buy rating, and zero Hold or Sell ratings. The mean price target is $22.67, representing a 2038.4% premium over the October 16, 2026 closing price of $1.06. For the fiscal year ending December 31, 2026, analysts expect revenue of $4.3M and an EPS of -$4.61. For the following fiscal year, 3 analysts project revenue of $8.8M, representing 105.0% growth, and an EPS of -$3.44. The company recorded 0 EPS beats over the last 4 quarters, with next earnings scheduled for November 18, 2026.
Key risks and what to watch
- Continued annual cash burn of -$14.6M could pressure liquidity against the existing $12.0M cash balance.
- Annual revenue has contracted at a 5-year CAGR of 2.7% from FY2020 through FY2025.
- Operating margin remains heavily negative at -487.8% on a trailing twelve months basis.
- The stock trades 88.1% below its 200-day moving average following a 1-year decline of 95.7%.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this ICCM AI stock analysis
This page is an AI-written research summary of IceCure Medical Ltd (ICCM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: ICCM income statement, ICCM balance sheet, ICCM key metrics, ICCM analyst forecast, ICCM chart. See the ICCM stock overview for the latest quote and news.
ICCM AI stock analysis FAQ
What is IceCure Medical's primary medical technology?
IceCure Medical develops cryoablation systems that freeze tumors in the human body, led by its ProSense system tailored for minimally invasive treatment of breast tumors.
What is IceCure Medical's current financial position?
As of June 30, 2026, IceCure Medical held $12.0M in cash and short-term investments, $90,000 in total debt, and net cash of $11.9M.
Does IceCure Medical pay a dividend?
IceCure Medical does not pay a dividend.
What are analysts forecasting for IceCure Medical's revenue and earnings?
For the fiscal year ending December 31, 2026, analysts estimate revenue of $4.3M and an EPS of -$4.61. For the following fiscal year, consensus models anticipate revenue to reach $8.8M alongside an EPS of -$3.44.